enGene Holdings Inc. is a clinical-stage biotechnology firm headquartered in Saint-Laurent, Canada, focused on pioneering genetic medicines for the targeted treatment of diseases affecting mucosal tissues and other organs. The company employs cutting-edge delivery technologies to improve the efficacy and safety of its proprietary therapeutic platform, addressing critical unmet medical needs in the field of genetic therapy. With its promising pipeline advancing through clinical trials, enGene is strategically positioned to transform the genetic medicine landscape and enhance patient outcomes across multiple therapeutic areas.